Global unity in the face of uncertainty, with Paul Romness and Farah Ahmad
On day three of BIO 2025, editor-in-chief Jonah Comstock caught up with OS Therapies CEO Paul Romness and EVERSANA VP of business development Farah Ahmad to discuss what they were seeing and hearing at the show.
In the video below, Romness briefly describes OS Therapies, a clinical stage biotech about to go to the FDA for a new treatment for osteosarcoma, a paediatric bone cancer. He talks about OS Therapies' new working relationship with EVERSANA.
Comstock, Romness, and Ahmad discuss the impressive turnout at the show this year and the importance of global collaboration. They talk a little bit about the current climate of uncertainty in the United States and how it’s negatively affecting biotech funding, and offer some advice for companies navigating the current environment. And they reflect on the importance of national and state governments continuing to support biomedical research and protect their own leadership in the space – and not “killing their golden goose”.
Learn more in the video below and be sure to visit our BIO Spotlight page for more coverage from the show.
